183 related articles for article (PubMed ID: 20735304)
1. Lapatinib and breast cancer: current indications and outlook for the future.
Moreira C; Kaklamani V
Expert Rev Anticancer Ther; 2010 Aug; 10(8):1171-82. PubMed ID: 20735304
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
Tevaarwerk AJ; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
[TBL] [Abstract][Full Text] [Related]
4. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Cameron DA; Stein S
Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
Halterman PA
Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
[TBL] [Abstract][Full Text] [Related]
7. Current and future anti-HER2 therapy in breast cancer.
Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
[TBL] [Abstract][Full Text] [Related]
8. An overview of HER-targeted therapy with lapatinib in breast cancer.
McArthur H
Adv Ther; 2009 Mar; 26(3):263-71. PubMed ID: 19365626
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer.
Amir E; Ocaña A; Seruga B; Freedman O; Clemons M
Cancer Treat Rev; 2010 Aug; 36(5):410-5. PubMed ID: 20100635
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib.
Voigtlaender M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
[TBL] [Abstract][Full Text] [Related]
11. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Constantinidou A; Smith I
Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer.
Paul B; Trovato JA; Thompson J
Am J Health Syst Pharm; 2008 Sep; 65(18):1703-10. PubMed ID: 18768996
[TBL] [Abstract][Full Text] [Related]
13. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
Lin NU; Diéras V; Paul D; Lossignol D; Christodoulou C; Stemmler HJ; Roché H; Liu MC; Greil R; Ciruelos E; Loibl S; Gori S; Wardley A; Yardley D; Brufsky A; Blum JL; Rubin SD; Dharan B; Steplewski K; Zembryki D; Oliva C; Roychowdhury D; Paoletti P; Winer EP
Clin Cancer Res; 2009 Feb; 15(4):1452-9. PubMed ID: 19228746
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.
Guarneri V
Expert Rev Anticancer Ther; 2009 Nov; 9(11):1549-57. PubMed ID: 19895239
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib in breast cancer: clinical experiences and future perspectives.
Giampaglia M; Chiuri VE; Tinelli A; De Laurentiis M; Silvestris N; Lorusso V
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S72-9. PubMed ID: 21129615
[TBL] [Abstract][Full Text] [Related]
16. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Andersson M; Kamby C
Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer.
Sardesai SD; Storniolo AM
Womens Health (Lond); 2015 Jun; 11(3):281-94. PubMed ID: 26102468
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib-associated toxicity and practical management recommendations.
Moy B; Goss PE
Oncologist; 2007 Jul; 12(7):756-65. PubMed ID: 17673607
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib: current status and future directions in breast cancer.
Moy B; Goss PE
Oncologist; 2006; 11(10):1047-57. PubMed ID: 17110623
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib in the treatment of HER-2 overexpressing breast cancer.
Vrdoljak E; Boban M; Ban M
J BUON; 2011; 16(3):393-9. PubMed ID: 22006739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]